Roivant Sciences Ltd.
ROIVNASDAQHealthcare● Active
$28.74
+$0.16(+0.56%)
Market Cap$20.7B
P/E Ratio—
52W High$32.793
52W Low$10.705
Roivant Sciences Ltd. (ROIV) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ROIV · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $8.26M | $29.05M | $32.71M | $31.53M | $55.29M |
| Cost of Revenue | $1.28M | $0.91M | $1.60M | $3.03M | $8.97M |
| Gross Profit | $6.97M | $28.14M | $31.11M | $28.50M | $46.32M |
| Gross Margin %(computed) | 84.44% | 96.86% | 95.11% | 90.38% | 83.78% |
| Operating Expenses | |||||
| R&D Expenses | $681.81M | $550.41M | $439.91M | $454.06M | $483.04M |
| G&A Expenses | $610.47M | $591.41M | $416.13M | $383.45M | $775.03M |
| Total Operating Expenses | $1292.28M | $1141.82M | $856.04M | $837.51M | $1258.07M |
| Operating Income | ($1285.30M) | ($1113.68M) | ($824.93M) | ($809.01M) | ($1211.75M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $178.11M | $258.38M | $146.43M | $32.18M | $0.37M |
| Interest Expense | $0.00M | $0.00M | $34.78M | $27.97M | $7.04M |
| Income Before Tax | ($264.58M) | ($681.59M) | $4567.86M | ($884.99M) | ($923.75M) |
| Income Tax Expense | $133.33M | $48.17M | $21.50M | $4.08M | $0.37M |
| Net Income | ($299.77M) | ($171.98M) | $4348.93M | ($1009.03M) | ($845.26M) |
| Net Margin %(computed) | — | -591.96% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.43 | $-0.24 | $5.55 | $-1.42 | $-1.26 |
| Wtd Avg Shares | 693.86M | 725.40M | 783.25M | 712.79M | 669.75M |
| EBITDA | ($1281.95M) | ($1099.61M) | ($802.89M) | ($790.16M) | ($910.77M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Roivant Sciences Ltd. data
About Roivant Sciences Ltd. (ROIV) Income Statement
Roivant Sciences Ltd. (ROIV) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, ROIV reported revenue of $0.01B, gross profit of $0.01B (gross margin 84.44%), and net income of ($0.30B) — a net profit margin of -3629.19%.
Frequently asked questions
ROIV · 4 questionsRoivant Sciences Ltd. (ROIV) reported revenue of $0.01B for 2026, down 71.6% year-over-year.
ROIV revenueROIV salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08